Deborah Ramsdell serves as Chief Operating Officer for Phoenix Tissue Repair and has over 30 years of experience in executive management and consulting roles in early and mid-stage biopharmaceutical companies. Ms. Ramsdell was involved in PTR-01’s early development at Lotus Tissue Repair, which was acquired by Shire prior to Phoenix Tissue Repair securing rights to the PTR-01 program. Over the course of her career, she has been responsible for the strategic design, leadership and operational oversight of multiple drug candidates in the fields of oncology, rare metabolic diseases, dermatology, pain, infectious diseases, transplantation, cardiology, renal diseases, and endocrinology. She has been CEO of Valerion Therapeutics since 2013, a clinical stage company developing a platform to treat rare glycogen storage disorders, which is under agreement with an acquirer. She is also CEO of Wings Therapeutics, a clinical stage company developing antisense oligonucleotides to treat a rare genetic dermatological disorder.